Core Viewpoint - Gestala Technology, the first domestic company focused on ultrasound brain-machine interfaces, has completed a 150 million yuan angel round financing, setting a record for the highest angel round financing in China's brain-machine interface sector [4][5]. Financing Details - The financing round was led by Guosheng Capital and Daotong Investment, with participation from several well-known investment institutions and companies, including Qingsong Capital and Gobi Partners [4]. - The funds raised will primarily be invested in product development and early clinical trials, focusing on core technology, clinical registration, AI integration, and advanced technology layout [6][7]. Industry Context - The global brain-machine interface industry is experiencing an investment boom, particularly in the "ultrasound track," with notable companies like Merge Labs and Nudge also securing significant funding [5]. - The advantages of ultrasound pathways over traditional invasive electrical methods include non-invasiveness, full-brain "reading and writing," and multi-target neural circuit regulation, addressing a wide range of clinical needs [5][6]. Product Development and Clinical Trials - Gestala Technology plans to establish its headquarters and first production line in Chengdu by the second quarter of this year, with the first product focusing on chronic pain management [6]. - Clinical trials have shown that a single stimulation can reduce pain scale scores by 50%, with effects lasting 1-2 weeks [6]. Strategic Vision - The company aims to create a brain-machine interface platform based on ultrasound with full-brain reading and writing capabilities, providing innovative treatment methods for various neurological diseases and exploring the integration of brain science and artificial intelligence [6][7].

Market Overview - The dollar index surged above 100, reaching its highest level since November of the previous year, while U.S. stock futures collectively declined, with the S&P 500 futures down 0.3%, Nasdaq 100 futures down nearly 0.5%, and Dow Jones futures down about 0.3% [1] - Global stock markets showed a downward trend, with multiple MSCI indices in the red, including the UK FTSE 100, France's CAC, and Germany's DAX, each down approximately 1% [1] - Bitcoin rose to $72,000, and Ethereum increased to $2,110.3, both gaining over 3% in the past 24 hours, while over 78,000 individuals faced liquidation [2] Currency Movements - The Japanese yen fell below 159.45 against the dollar for the first time since July 2024, while the South Korean won dropped below the 1,500 mark, reaching a two-week high [3] - The euro fell to 1.1467 against the dollar, marking its lowest level since August of the previous year [3] - The offshore yuan fell below the 6.9 mark against the dollar, with the onshore yuan closing at 6.9030, a decrease of 278 points from the previous trading day [3] Commodity Prices - International oil prices experienced significant volatility, with ICE Brent crude initially surging by 2% before narrowing its gains to 0.6% [2] - Gold and silver prices declined, with spot silver dropping below $82 per ounce, down over 2% for the day, and spot gold falling by 0.27% [2] Geopolitical Events Impacting Energy Sector - Reports indicated that Iran has begun laying mines in the Strait of Hormuz, which could impact shipping routes, although Iranian officials denied these claims [4] - The U.S. and Israel's military actions against Iran have led several major energy companies operating in the Middle East, including TotalEnergies, Abu Dhabi National Oil Company, Kuwait Petroleum Corporation, and Qatar LNG, to announce production cuts or suspensions [5]

Core Insights - The article highlights the transformative potential of brain-computer interfaces (BCIs), exemplified by Nolan Abbot's experience with Neuralink, marking a significant leap from science fiction to reality [4][6]. - BCIs have been officially recognized in China's government work report, elevating their status as a core future industry alongside quantum technology and 6G [8][10]. Government Recognition - In March 2024, BCIs were mentioned in the government work report for the first time, indicating their strategic importance and transition from experimental research to a national priority [10][11]. - The development trajectory of BCIs has seen significant policy support over the past decade, culminating in their inclusion in the 2026 government work report [10][11]. Global Competition - The BCI field is characterized by a global race for technological leadership, with different approaches: invasive, semi-invasive, and non-invasive methods, each catering to various applications [12][13]. - The U.S. leads in invasive BCIs with companies like Neuralink, while China is catching up in clinical trials and technology development [13][14][17]. Market Dynamics - The global BCI market is projected to grow from approximately $2.62 billion in 2024 to $12.4 billion by 2034, with China's market expected to reach 5.58 billion yuan by 2027, reflecting a 20% annual growth rate [20][21]. - Over 200 BCI companies have emerged in China, establishing a complete industrial chain from materials to applications, with healthcare being the most promising sector [20][21]. Challenges and Pathways - Key challenges include reliance on imported core technologies, a lack of standardized data for training algorithms, and the absence of ethical and regulatory frameworks [23][24]. - Recommendations include establishing national innovation centers for BCIs and creating a high-quality database for brain-machine interaction data [24]. Future Implications - BCIs are poised to redefine human-machine relationships, enhancing cognitive abilities and enabling seamless interaction between humans and AI systems [25]. - The successful integration of BCIs into daily life could lead to unprecedented changes in how humans interact with technology and each other [25][26].

Investment Rating - The report maintains a "Market Weight" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [4][25]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 2.64% from February 27, 2026, to March 12, 2026, which is approximately 1.81 percentage points lower than the index [11]. - Most sub-sectors within the industry recorded negative returns during the same period, with in vitro diagnostics and medical consumables showing positive growth of 3.49% and 1.71%, respectively, while medical R&D outsourcing and medical devices experienced declines of 4.85% and 4.25% [12]. - Approximately 31% of stocks in the industry recorded positive returns, while 69% experienced negative returns, with notable performers including Shengjitang, which saw a weekly increase of 38.81% [13][16]. - The overall industry valuation has decreased, with the SW pharmaceutical and biotechnology industry index's PE (TTM) at approximately 49.25 times, which is 3.63 times higher than the CSI 300 index [17][25]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, with a decline of 2.64% from February 27, 2026, to March 12, 2026 [11]. - Most sub-sectors recorded negative returns, with in vitro diagnostics and medical consumables performing better [12]. - About 31% of stocks in the industry had positive returns, with significant fluctuations in individual stock performances [16]. 2. Industry News - A new procurement regulation was issued by the Jiangxi Medical Insurance Bureau, aiming to unify the procurement of drugs and medical consumables within county-level medical communities, addressing issues of fragmented management and weak bargaining power [23]. - The Jiangsu Provincial Government released an action plan to promote the development of the brain-computer interface industry, targeting the establishment of several innovative products and companies by 2030 [22]. 3. Company Announcements - Huadong Medicine announced that its subsidiary received FDA approval for a new drug clinical trial, which is a significant milestone for the company [24]. 4. Industry Outlook - The report suggests that the investment risk-reward ratio is improving in the innovation drug sector, recommending attention to various segments including medical devices, pharmaceutical commerce, aesthetic medicine, scientific services, and traditional Chinese medicine [25][26].

Core Viewpoint - The approval of the first invasive brain-computer interface (BCI) medical device by the National Medical Products Administration marks a significant milestone in clinical applications, with the company BoRuiKang Medical Technology (Shanghai) Co., Ltd. initiating its IPO process simultaneously [1][4]. Group 1: Product Overview - The approved product consists of a brain-computer interface implant, an electrode kit, a signal transceiver, a pneumatic glove device, a surgical toolkit, and software for decoding brain signals and clinical management [3]. - It is designed for patients aged 18 to 60 with cervical spinal cord injuries resulting in quadriplegia, specifically those with stable conditions for at least six months [3]. Group 2: Technology and Innovation - The NEO system, developed in collaboration with Tsinghua University, utilizes a minimally invasive approach with a wireless power and communication design, avoiding direct contact with brain tissue [4][5]. - Clinical trials have shown significant improvements in hand function for participants, with some achieving independent grasping and basic daily activities [5]. Group 3: Market Growth - The global implanted BCI market is projected to grow from approximately $153 million in 2026 to about $252 million by 2030, with a compound annual growth rate (CAGR) of around 13% [6]. - The Chinese BCI market is expected to reach approximately 46 billion yuan in 2026, with long-term projections suggesting it could exceed 120 billion yuan by 2040 [6]. Group 4: Policy and Industry Dynamics - The BCI technology has been included in China's "14th Five-Year Plan," with government support aimed at achieving key technological breakthroughs by 2027 [7]. - The competitive landscape is intensifying, with BoRuiKang leading in semi-invasive technology while other companies pursue fully invasive approaches [7]. Group 5: Future Outlook - The BCI industry is transitioning from research to commercialization, with BoRuiKang's NEO system positioning Chinese enterprises favorably in this emerging market [8]. - The potential for large-scale application of BCI technology could create new opportunities in the medical industry, particularly for the rehabilitation of millions of spinal cord injury patients [8].

Market Overview - Major stock indices in the Asia-Pacific region, including Japan, South Korea, Australia, and New Zealand, experienced collective declines, with the Shanghai Composite Index dropping by 0.82% and the Shenzhen Component Index falling by 0.65% [1][2] - The trading volume reached 2.4 trillion yuan, with over 3,600 stocks declining [2] Sector Performance - The chemical sector continued its strong performance, with stocks like Sanfangxiang and Luhua Technology achieving two consecutive daily limits, while Jinzhengdai and Hongbaoli also hit the daily limit [6] - The wind power sector showed volatility, with stocks such as Daikin Heavy Industries and Tongyu Heavy Industries reaching daily limits [6] Emerging Concepts - The controlled nuclear fusion concept saw a rapid rise, with China National Nuclear Corporation hitting the daily limit and a market capitalization nearing 58 billion yuan [7] - The brain-computer interface concept experienced significant gains, with stocks like Innovation Medical and Sanbo Brain Science rising nearly 10% following the approval of the first invasive brain-computer interface medical device by the National Medical Products Administration [7] Commodity Market - In the commodity market, both crude oil and silver saw increased declines, with spot silver dropping below $82 per ounce and WTI crude oil futures falling by 1% to $93.388 per barrel [7] Other Markets - The Hang Seng Index and Hang Seng Tech Index both fell by 1%, while Yao Cai Securities surged over 40% during the afternoon session, reaching a market capitalization of over 16 billion Hong Kong dollars [7] - The Nikkei 225 index dropped by 1.16% for the week, while the Korean Composite Index fell by 1.72% [10]

本文字数：3935，阅读时长大约8分钟 作者 | 第一 财经 金叶子 作为首批布局脑机接口的城市，上海又实现了关键一跃。 2026.03. 13 国家药监局官网13日公布，近日国家药监局批准了博睿康医疗科技（上海）有限公司植入式脑机接口手部运动功能代偿系统创新产品注册申请，实现 脑机接口医疗器械全球首发上市，标志着国际首个侵入式脑机接口医疗器械进入临床应用阶段。 从2023年进入临床试验至今，博睿康的产品已由复旦大学附属华山医院、首都医科大学宣武医院联合其他临床试验中心完成了共36例颈段脊髓损伤截 瘫患者的植入手术，其中预临床4例，多中心临床32例。所有患者均成功实现居家脑控抓握辅助与康复训练，在主要临床终点上100%达标，且未见医 疗器械相关严重不良事件，初步验证了硬膜外微创植入路径的安全性和长期使用可行性。 博睿康的 NEO （微创硬膜外脑机接口） 由于脑机接口横跨神经科学、材料学、微电子等多个学科，"技术落地"与"商业化"之间横亘着一条巨大的鸿 沟。在这场全国乃至全球的产业竞逐中，上海的突围路径显得尤为清晰：并非单纯依靠政策补贴或硬件制造，而是凭借难以复制的"基础研究+技术转化 ＋顶级临床"资源，上海已 ...

Core Viewpoint - The article highlights the recent surge in brain-computer interface (BCI) concept stocks, particularly following the approval of a groundbreaking BCI medical device by the National Medical Products Administration of China, which is set to enhance the quality of life for patients with quadriplegia [1][4]. Group 1: Market Reaction - On March 13, brain-computer interface concept stocks experienced significant movement, with companies like Innovation Medical and Sanbo Brain Science seeing their shares rise nearly 10% [1]. - Innovation Medical's stock price increased by 5.55%, closing at 31.40, with a trading volume of 640,200 shares and a total transaction amount of 1.96 billion [2]. Group 2: Product Approval and Features - The National Medical Products Administration approved the registration application for a novel implanted brain-computer interface system by Borekan Medical Technology, marking the first global launch of such a medical device [4]. - The product includes components such as an implanted brain-computer interface, brain electrode kit, signal transceiver, pneumatic glove, surgical tool kit, and software for decoding brain signals and clinical management [4]. - It is designed for patients aged 18 to 60 with cervical spinal cord injuries, specifically those classified as A to C on the ASIA scale, who have stable conditions for at least six months and cannot perform hand grasping [4].

Core Viewpoint - The approval of the brain-machine interface hand function compensation system by the National Medical Products Administration marks the global launch of the first invasive brain-machine interface medical device, entering the clinical application phase [1]. Group 1: Product Overview - The product consists of several components including an implanted brain-machine interface, a set of implanted EEG electrodes, a brain signal transceiver, a pneumatic glove device, a disposable surgical tool kit, EEG decoding software, medical testing software, and clinical management software [1]. - It is designed for patients with quadriplegia due to cervical spinal cord injuries, specifically those aged 18 to 60 with C2 to C6 spinal injury ratings of A to C, who have had a stable condition for at least six months after standardized treatment [1]. Group 2: Clinical Application and Results - The product utilizes minimally invasive implantation techniques and wireless power communication technology [1]. - Clinical trial results indicate that subjects using this product have significantly improved their hand grasping abilities, thereby enhancing their quality of life [1].

据央视新闻，近日，国家药监局批准了博睿康医疗科技（上海）有限公司植入式脑机接口手部运动功能代偿系统创新产品注册申请，实现脑 机接口医疗器械全球首发上市，标志着国际首个侵入式脑机接口医疗器械进入临床应用阶段。 该产品由脑机接口植入体、植入式脑电电极套件、脑电信号收发器、气动手套设备、一次性手术工具包、脑电解码软件、医用测试软件、临床管理 软件组成。适用于颈段脊髓损伤所致四肢瘫患者，通过气动手套设备辅助实现手部的抓握功能代偿。 患者需满足以下条件：18岁到60岁，C2～ C6颈段脊髓损伤评级A～C级的四肢瘫，疾病确诊超过1年且经规范治疗后病情稳定至少6个月，手部无法完成抓握，上臂尚存部分功能。该 产品采用硬脑膜外微创植入与无线供能通信技术，临床试验结果显示，受试者通过该产品实现了手部抓握能力的明显提高，进而改善患者生 活质量。 ...